Secondary analysis of the LAURA RCT in unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy: patient-reported quality of life, functioning and symptoms were not substantially different with osimertinib vs placebo (global QoL deterioration HR 1.14).
Secondary analysis
Arriola et al. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy